Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00718419 · ClinicalTrials.gov registry record · Phase 2
A Study for Patients That Have Been Previously Been Treated in Waldenstrom's Macroglobulinemia or Multiple Myeloma
A Phase 2 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 2
- Development phase
- 56
- Enrollment target
NCT00718419 is a Phase 2 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 56 participants.
The verdict
NCT00718419, a Phase 2 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 56 participants
- Enrollment target
Study Summary
To determine whether further study of single-agent enzastaurin is warranted in patients with previously treated Waldenstrom's Macroglobulinemia or Multiple Myeloma based on response.
Interventions
- DRUG Enzastaurin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 56 participants |
| Start Date | 2008-07 |
| Est. Completion | 2012-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00718419
The ClinicalTrials.gov registry entry for NCT00718419 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 56 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Enzastaurin is the first listed.
NCT00718419 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00718419 about?
NCT00718419 is a clinical study titled "A Study for Patients That Have Been Previously Been Treated in Waldenstrom's Macroglobulinemia or Multiple Myeloma". To determine whether further study of single-agent enzastaurin is warranted in patients with previously treated Waldenstrom's Macroglobulinemia or Multiple Myeloma based on response.
What is the current status of trial NCT00718419?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 56 participants. The study started on 2008-07. Estimated completion is 2012-08.
What interventions are being tested in trial NCT00718419?
The interventions under investigation include: Enzastaurin (DRUG).
Who is sponsoring clinical trial NCT00718419?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.